Bank of New York Mellon’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q2 | – | Sell |
-22,977
| Closed | -$24K | – | 4385 |
|
|
2019
Q1 | $24K | Sell |
22,977
-561
| -2% | -$457 | ﹤0.01% | 4152 |
|
|
2018
Q4 | $18K | Hold |
23,538
| – | – | ﹤0.01% | 4170 |
|
|
2018
Q3 | $50K | Sell |
23,538
-1
| -0% | -$2 | ﹤0.01% | 4128 |
|
|
2018
Q2 | $54K | Sell |
23,539
-3,414
| -13% | -$9.94K | ﹤0.01% | 4085 |
|
|
2018
Q1 | $86K | Sell |
26,953
-1,754
| -6% | -$4.83K | ﹤0.01% | 4088 |
|
|
2017
Q4 | $117K | Buy |
28,707
+5,169
| +22% | +$22.5K | ﹤0.01% | 4061 |
|
|
2017
Q3 | $106K | Sell |
23,538
-1
| -0% | -$4 | ﹤0.01% | 3999 |
|
|
2017
Q2 | $78K | Sell |
23,539
-85,734
| -78% | -$356K | ﹤0.01% | 4070 |
|
|
2017
Q1 | $1.01M | Buy |
109,273
+5,305
| +5% | +$46.6K | ﹤0.01% | 3236 |
|
|
2016
Q4 | $802K | Buy |
103,968
+1,621
| +2% | +$14.9K | ﹤0.01% | 3382 |
|
|
2016
Q3 | $1.17M | Buy |
102,347
+12,528
| +14% | +$146K | ﹤0.01% | 3086 |
|
|
2016
Q2 | $1.11M | Buy |
89,819
+4,226
| +5% | +$51.3K | ﹤0.01% | 3071 |
|
|
2016
Q1 | $865K | Buy |
85,593
+21,037
| +33% | +$247K | ﹤0.01% | 3150 |
|
|
2015
Q4 | $1.46M | Buy |
64,556
+373
| +0.6% | +$7.64K | ﹤0.01% | 2906 |
|
|
2015
Q3 | $1.06M | Sell |
64,183
-7,979
| -11% | -$160K | ﹤0.01% | 3144 |
|
|
2015
Q2 | $1.62M | Buy |
72,162
+16,802
| +30% | +$414K | ﹤0.01% | 3057 |
|
|
2015
Q1 | $1.43M | Sell |
55,360
-9,751
| -15% | -$247K | ﹤0.01% | 3090 |
|
|
2014
Q4 | $1.42M | Buy |
65,111
+2,970
| +5% | +$60.8K | ﹤0.01% | 3086 |
|
|
2014
Q3 | $1.18M | Buy |
62,141
+9,422
| +18% | +$189K | ﹤0.01% | 3194 |
|
|
2014
Q2 | $1.23M | Buy |
52,719
+21,937
| +71% | +$542K | ﹤0.01% | 3194 |
|
|
2014
Q1 | $1.04M | Buy |
30,782
+11,553
| +60% | +$389K | ﹤0.01% | 3253 |
|
|
2013
Q4 | $567K | Buy |
+19,229
| New | +$352K | ﹤0.01% | 3538 |
|
Bank of New York Mellon's OMED Position: Q2 2019 in Review
Bank of New York Mellon sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q2 2019, closing a stake of 22,977 shares — an estimated $24K sold.
Bank of New York Mellon first reported a position in OMED in Q4 2013 and held it in 22 quarters. The position peaked at $1.62M in Q2 2015. 0 funds tracked by Wall St. Rank hold OMED as of Q2 2019.
- Bank of New York Mellon reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q2 2019 after selling out during the quarter.
- Bank of New York Mellon sold 22,977 OncoMed Pharmaceuticals, Inc. shares in Q2 2019, an estimated $24K.
- Bank of New York Mellon first reported a position in OncoMed Pharmaceuticals, Inc. in Q4 2013 and held it in 22 quarters.
- Bank of New York Mellon's OncoMed Pharmaceuticals, Inc. position peaked at $1.62M in Q2 2015.
- 0 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q2 2019.
Based on Bank of New York Mellon's 13F filing for Q2 2019, filed 12 Aug 2019.